Overview A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes Status: Completed Trial end date: 2020-07-31 Target enrollment: Participant gender: Summary An open label, Phase 1, study of AMV564 as monotherapy to assess the safety and efficacy in patients with Myelodysplastic Syndromes Phase: Phase 1 Details Lead Sponsor: Amphivena Therapeutics, Inc.